Trial Profile

A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Jan 2026 Planned End Date changed from 29 Oct 2025 to 29 Oct 2026.
05 Feb 2025 Planned End Date changed from 5 Jan 2025 to 29 Oct 2025.
01 Apr 2023 Results published in the Nature Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com